Program
Artesunate
Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.
Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.
Drug pageArtesunate: every studyMany companies study it; this page follows only the 17 they lead. All 115 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 60 open or running | phase 4since Mar 8, 2007 | Apr 18, 2006 | none ahead |
| Frantz Viral Therapeuticsits history only | 44 open or running | phase 2since Sep 19, 2019 | Sep 19, 2019 | Dec 2026phase 2 · NCT06075264 |
| Metanoic Healthits history only | 22 open or running | phase 2since Jul 7, 2025 | Jul 7, 2025 | Jun 30, 2027phase 2 · NCT07095478 |
| Shin Poong Pharmaceuticalits history only | 20 open or running | phase 2since Sep 13, 2018 | Sep 13, 2018 | none ahead |
| Amivasits history only | 11 open or running | phase 2since Feb 25, 2025 | Feb 25, 2025 | May 31, 2028phase 2 · NCT06853184 |
| Pfizerits history only | 10 open or running | phase 1since May 4, 2009 | May 4, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 4since Sep 10, 2009 | Sep 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 18, 2006.
- Oct 10, 2006Phase 1 study in MalariaSanofi · NCT00386503 · 22 enrolled · France
- Mar 8, 20072 phase 4 studies in MalariaSanofi · NCT00445796, NCT00452907
- May 4, 2009Pfizer’s first study: phase 1 study in Malaria, FalciparumNew to PfizerPfizer · NCT00894374 · 40 enrolled · Singapore
- Sep 10, 2009Teva Pharmaceutical Industries’ first study: phase 4 study in MalariaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00978172 · 220 enrolled · Cameroon
- Dec 1, 2009Phase 4 study in MalariaSanofi · NCT01023399 · 580 enrolled · Côte D'Ivoire
- Jun 20, 2011Phase 3 study in MalariaSanofi · NCT01378286 · 380 enrolled · Brazil
- Sep 13, 2018Shin Poong Pharmaceutical’s first study: phase 2 study in Malaria, FalciparumNew to Shin Poong PharmaceuticalShin Poong Pharmaceutical · NCT03814616 · 300 enrolled · Gambia, Zambia
- Sep 19, 2019Frantz Viral Therapeutics’ first study: phase 2 study in Papillomavirus InfectionsNew to Frantz Viral TherapeuticsFrantz Viral Therapeutics · NCT04098744 · 78 planned · United States
- Aug 26, 2020Phase 2 study in COVID-19Shin Poong Pharmaceutical · NCT04532931 · 192 enrolled · South Africa
- Sep 22, 2022Phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862 · 17 enrolled · United States
- Oct 4, 2023Phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264 · 27 planned · United States
- Jan 3, 2024Phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564 · 48 planned · United States
- Feb 25, 2025Amivas’ first study: phase 2 study in Cytomegalovirus InfectionsNew to AmivasAmivas · NCT06853184 · 90 planned · United States, Australia
- Jul 7, 2025Metanoic Health’s first studies: 2 phase 2 studiesNew to Metanoic HealthMetanoic Health · NCT07095478, NCT07095309
Ahead
- Dec 2026Primary completion: phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264
- Dec 28, 2026Primary completion: phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862
- Dec 31, 2026Primary completion: phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564
- Jun 30, 2027Primary completion: phase 2 study in CIN 2/3Metanoic Health · NCT07095478
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07095478CIN 2/3 · Malaysia | 2 | Not yet recruiting | Metanoic Health | Jun 30, 2027 | 28 |
| NCT07095309Intestinal Neoplasms · Malaysia | 2 | Not yet recruiting | Metanoic Health | Aug 30, 2032 | 120 |
| NCT06853184Cytomegalovirus Infections · United States, Australia | 2 | Recruiting | Amivas | May 31, 2028 | 90 |
| NCT06206564Anal High-grade Squamous Intraepithelial Lesion · United States | 2 | Recruiting | Frantz Viral Therapeutics | Dec 31, 2026 | 48 |
| NCT06075264Vulvar Diseases · United States | 2 | Recruiting | Frantz Viral Therapeutics | Dec 2026 | 27 |
| NCT05555862Papillomavirus Infections · United States | 2 | Active, not recruiting | Frantz Viral Therapeutics | Dec 28, 2026 | 17 |
| NCT04532931COVID-19 · South Africa | 2 | Completed | Shin Poong Pharmaceutical | Aug 5, 2021 | 192 |
| NCT04098744Papillomavirus Infections · United States | 2 | Recruiting | Frantz Viral Therapeutics | Jul 31, 2026 | 78 |
| NCT03814616Malaria, Falciparum · Gambia, Zambia | 2 | UNKNOWN | Shin Poong Pharmaceutical | Oct 2019 | 300 |
| NCT01378286Malaria · Brazil | 3 | Completed | Sanofi | Jun 2013 | 380 |
| NCT01023399Malaria · Côte D'Ivoire | 4 | Completed | Sanofi | Oct 2013 | 580 |
| NCT00978172Malaria · Cameroon | 4 | Completed | Teva Pharmaceutical Industries | 220 | |
| NCT00894374Malaria, Falciparum · Singapore | 1 | Completed | Pfizer | Aug 2009 | 40 |
| NCT00452907Malaria · Mali | 4 | Completed | Sanofi | Jun 2007 | 780 |
| NCT00445796Malaria · Cameroon, Senegal | 4 | Completed | Sanofi | 300 | |
| NCT00386503Malaria · France | 1 | Completed | Sanofi | Dec 2006 | 22 |
| NCT00316329Malaria · Cameroon, Madagascar, Mali and more | 3 | Completed | Sanofi | 1,032 |
How it is read
Names in the registry
- “Artesunate”, 6 entries
- “Artesunate + Amodiaquine”, 3 entries
- “Artesunate ointment”, 2 entries
- “Artesunate vaginal insert”, 1 entry
- “Artesunate-amodiaquine”, 1 entry
Conditions, from the studies’ own filings
- Malaria, 7 studies
- Papillomavirus Infections, 3 studies
- Malaria, Falciparum, 2 studies
- Cytomegalovirus Infections, 1 study
- Vulvar Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.